Centre for the Evaluation of Vaccination, Vaccine & Infectious Diseases, University of Antwerp 

Additionally, Novosanis collaborates on several projects with the Centre for the Evaluation of Vaccination, Vaccine & Infectious Diseases. Prof. Alex Vorsters and his team work on biomarkers in first-void urine for improved diagnosis and monitoring of cervical (pre)cancer  - https://novosanis.com/our-products/posters-publications/human-papillomavirus-detection-urine-effect-first-void-urine

Disclaimer

Novosanis is a wholly owned subsidiary of OraSure Technologies, Inc. (NASDAQ: OSUR), and an innovative developer and producer of medical devices improving the quality of diagnostic tests for infectious diseases and oncology. The Colli-Pee® family, the heart of the company, allows volumetric and standardized collection of first-void urine. The platform consists of variants capturing a range of urine volumes for different application purposes. Urine collection through the Colli-Pee® device is easy, comfortable, and more accurate than a regular urine cup. First-void urine has shown to improve detection of infectious diseases, including sexually transmitted infections as well as for some cancers applications. The Colli-Pee® device enables immediate mixing of the first-void urine sample with a preservative, improving stability of the urine specimen. Novosanis markets its products worldwide and has a global customer base.